Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03065790 · ClinicalTrials.gov registry record
Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- 1
- Enrollment target
NCT03065790: Clinical Trial study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT03065790 is a clinical trial that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03065790 was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
Adult patients with non-Hodgkin lymphoma who will be treated with lenalidomide will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated response and long term outcomes.
Interventions
- DIAGNOSTIC_TEST 2-Deoxy-2-[18F]fluoro-D-glucose (FDG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-02-06 |
| Est. Completion | 2021-04-28 |
Why NCT03065790 stopped before completion
NCT03065790 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) is the first listed.
NCT03065790 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03065790 about?
NCT03065790 is a clinical study titled "Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide". Adult patients with non-Hodgkin lymphoma who will be treated with lenalidomide will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated response and long term outcomes.
What is the current status of trial NCT03065790?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2017-02-06. Estimated completion is 2021-04-28.
What interventions are being tested in trial NCT03065790?
The interventions under investigation include: 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03065790?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI